TABLE 2.
Comparison of AE signal intensity under different administration routes.
| PT | a | ROR | ROR (95%Cl) | |
|---|---|---|---|---|
| OBSTRUCTIVE PANCREATITIS | 3 | 62.37 | 62.37 (20.03–194.22) | |
| KETOSIS | 5 | 60.44 | 60.44 (25.07–145.7) | |
| THYROID CYST | 3 | 48.38 | 48.38 (15.55–150.52) | |
| EUGLYCAEMIC DIABETIC KETOACIDOSIS | 9 | 29.74 | 29.74 (15.45–57.26) | |
| ADENOCARCINOMA PANCREAS | 4 | 29.42 | 29.42 (11.02–78.56) | |
| VITH NERVE PARALYSIS | 3 | 26.38 | 26.38 (8.49–81.97) | |
| HYPERGLYCAEMIC HYPEROSMOLAR NONKETOTIC SYNDROME | 3 | 25.73 | 25.73 (8.28–79.93) | |
| Oral | NECK MASS | 7 | 25.24 | 25.24 (12.02–53.03) |
| ERUCTATION | 35 | 21.68 | 21.68 (15.54–30.24) | |
| GLYCOSYLATED HAEMOGLOBIN INCREASED | 51 | 21.52 | 21.52 (16.33–28.36) | |
| IMPAIRED GASTRIC EMPTYING | 15 | 19.86 | 19.86 (11.96–32.99) | |
| PANCREATITIS | 100 | 19.45 | 19.45 (15.96–23.7) | |
| BILE DUCT STONE | 6 | 19.02 | 19.02 (8.53–42.39) | |
| DIABETIC RETINOPATHY | 6 | 17.91 | 17.91 (8.04–39.91) | |
| VERTIGO POSITIONAL | 3 | 17.41 | 17.41 (5.61–54.04) | |
| MEDULLARY THYROID CANCER | 16 | 76.64 | 76.64 (46.15–127.27) | |
| ALLODYNIA | 30 | 51.42 | 51.42 (35.64–74.17) | |
| STARVATION KETOACIDOSIS | 3 | 46.85 | 46.85 (14.74–148.84) | |
| GASTRIC HYPOMOTILITY | 5 | 36.65 | 36.65 (15.03–89.37) | |
| ERUCTATION | 441 | 35.27 | 35.27 (32.06–38.79) | |
| OBSTRUCTIVE PANCREATITIS | 12 | 31.85 | 31.85 (17.94–56.56) | |
| FOLLICULAR THYROID CANCER | 3 | 24.49 | 24.49 (7.8–76.91) | |
| Subcutaneous | DIABETIC RETINOPATHY | 63 | 23.97 | 23.97 (18.67–30.78) |
| MESENTERIC PANNICULITIS | 5 | 23.32 | 23.32 (9.62–56.57) | |
| GLYCOSYLATED HAEMOGLOBIN DECREASED | 26 | 22.73 | 22.73 (15.41–33.52) | |
| THYROID MASS | 54 | 19.88 | 19.88 (15.18–26.02) | |
| BILE ACID MALABSORPTION | 3 | 19.13 | 19.13 (6.11–59.9) | |
| VOMITING PROJECTILE | 36 | 18.14 | 18.14 (13.05–25.22) | |
| RETINOPATHY | 49 | 16.42 | 16.42 (12.38–21.78) | |
| NECK MASS | 33 | 15.02 | 15.02 (10.65–21.19) |
Note: a, number of cases with available.